Concernant les diverses indemnités de départs convenues au bénéfice des dirigeants, bien que les montants maximum des indemnités soient en ligne avec le plafond de 12 mois de rémunération salariale (fixe + bonus annuel) fixé par Proxinvest, les motifs donnant droit au versement de celles-ci ne respectent pas la politique de Proxinvest qui en limite le versement à la seule hypothèse d’un départ contraint et lié à changement de contrôle.
La résolution 17 relative à l’approbation des principes de détermination des éléments de rémunération des dirigeants pour l’exercice 2017 ne peut être soutenue en raison d’un manque de transparence de la société.
Par ailleurs, le conseil est indépendant à 85,71% selon Proxinvest, ce qui est satisfaisant. Ainsi, Proxinvest soutient le renouvellement, la ratification et la nomination des administrateurs proposés aux résolutions 19, 20 et 21.
Erytech Pharma is a pharmaceutical company based in France. Co. is primarily engaged in developing cancer therapies that work by starving tumors. Co.'s first product (ERY-ASP), which is in phase III development, provides a therapeutic solution to frail patients with acute leukemia. Co.'s proprietary technology is based on encapsulation of therapeutic molecules into red blood cells. Co. maintains a production unit located in Lyons with "Pharmaceutical Establishment" status. Co. has also signed two distribution partnership agreements with the Orphan Europe-Recordati company and the TEVA group.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Based on the last sets of results and quarterly sales, it seems that the improvement in the US and the many initiatives taken by the new CEO have placed Virbac on the path to an estimated operating margin of 14.5% in 2023. Our target price of € 185 suggests more limited upside in the short term (7%): Neutral vs Buy. - Cf. report published this morning. - ...
>A collaborative agreement... - Erytech Pharma announced yesterday evening that it had entered into a strategic agreement with US company SQZ Biotech, which is specialised in cell therapies, aimed at developing a portfolio of new red-blood-cell-based immune modulation treatments. To this end, Erytech is eligible to receive up to $ 57m (up-front payment + regulatory milestone payments) and up to $ 50m in commercial milestone payments per approved treatment as well as p...
Sur la base des derniers chiffres publiés, il apparaît que l’amélioration de la situation aux USA et les nombreuses initiatives du nouveau CEO ont engagé Virbac dans une trajectoire convergeant vers une MOP de 14.5%e à horizon 2023. Notre objectif de cours de 185 € suggère un potentiel plus limité à court terme (7%) : Neutre vs Achat. - Cf. étude publiée ce jour. - ...
On 9 May 2019, the Company issued convertible bonds for a total principal amount of EUR 150 million. The sole agenda item relates to the proposed approval and ratification, in accordance with Article 556 of the Belgian Companies Code, of conditions of the convertible bonds in case of a change of control. These are standard provisions and they are in line with the market practice. Hence, we see no reason for shareholder concern and recommend to approve.
General: Hella is a leading automotive supplier with over 125 locations in some 35 countries. In financial year 2018/2019, the Company generated sales of EUR 7.0bn with around 39,000 employees. Hella specialises in innovative lighting systems and vehicle electronics in its segments Automotive and Aftermarket. Furthermore, in its Special Applications segment, Hella develops, manufactures and sells lighting and electronic products for specialist vehicles. As of 31 May 2019, a total of 60.00% of the Company's shares were covered by a pool agreement of family shareholders. A total of 62 members o...
In general, NN Group is in compliance with the Dutch regulations relating to the organisation and procedures of the Extraordinary General Meeting. On August 12, 2019, the Company announced that Mr. Lard Friese stepped down as CEO of the Company to become the new CEO of Dutch competitor Aegon. ECGS notes that the sole agenda item of this EGM (ITEM 2) concerns the intended appointment of Mr. David Knibbe as CEO and member of the executive board of NN Group. According to Dutch law and the Company's Articles of Association, shareholders are NOT entitled to vote on such agenda item; it is a discus...
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.